ClinicalTrials.gg
TerminatedNCT03471702Updated Jul 11, 2019

A Secondary Study Evaluating Aqueduct's Smart External Drain (SED)

An interventional study of Smart External Drain - SED in Hydrocephalus, Hydrocephalus in Children and Tumor, Brain, sponsored by Aqueduct Critical Care. Terminated at 3 sites in United States. Open to participants aged Up to 80 Years. Per ClinicalTrials.gov, last updated 2019-07-11.

Sponsored by Aqueduct Critical Care · Not applicable, Interventional, and Treatment

Why this study was terminated
Device Review performed by Sponsor

From the registry’s dates

  • Primary completion was Nov 2018, 8 years ago, and no results have been posted to the registry.
Phase
Not applicable
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
Up to 80 Years
Sex
All
01

Study summary

Aqueduct's Smart External Drain (SED) will be compared to the current gold standard for temporary CSF management in a hospital setting.

  • Evaluate the number of subjects requiring to be switched to a standard of care EVD
  • Evaluate subject transport while on the SED
  • Evaluate SED system control from initiation of SED through discharge of external drain system
Read the detailed description

This clinical trial will evaluate Aqueduct's Smart External Drain (SED) upon implementation of ventriculostomy or lumbar drain placement for temporary CSF external management in a hospital setting. Subjects will remain on study from the time of SED application through discharge of the external drain or switch to standard of care extraventricular drain.

02

Conditions studied

  • Hydrocephalus
  • Hydrocephalus in Children
  • Tumor, Brain
  • Subarachnoid Hemorrhage
03

In context

Hydrocephalus

190 studies on the registry are indexed under Hydrocephalus; 52 are open to participants now.

This study's enrollment of 12 is below the median of 41 across 97 interventional studies indexed under Hydrocephalus.

Browse Hydrocephalus studies →

Lead sponsor

Aqueduct Critical Care is the lead sponsor of 2 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Up to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject scheduled to have an external drain (includes extra-ventricular and lumbar drains) placed as part of routine management.
  2. Age 0-80.
  3. Able to obtain consent or legally authorized representative (LAR) consents for subject to be treated on study.

Exclusion criteria

Exclusion Criteria:

  1. Anticoagulant therapy (does not include DVT or PE prophylaxis).
  2. Known bleeding diathesis.
  3. Scalp infection.
  4. In the opinion of the Investigator the subject is not a good study candidate.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Single Arm Study

    All subjects enrolled on study will utilize Aqueduct's Smart External Drain (SED) from the time of external drain implementation until end of study upon discharge of SED or switch to standard of care external drain.

    Device: Smart External Drain - SED

Interventions

  • DeviceSmart External Drain - SED

    Aqueduct's Smart External Drain (SED) is a gravity based system which utilizes a proprietary reference shroud which eliminates the need for manual adjustment of the system in the external management of CSF drainage.

06

What researchers measure

Primary outcomes

  1. The number of subjects which require switching to a standard of care external drain.

    Evaluating the number of subjects which require switching to a standard of care external drain versus the number of subjects which remain on the SED until study completion or discharge of the external drain.

    Time frame: The study review and data collection period will begin at the time SED is connected to the ventriculostomy catheter until discharge of ventriculostomy catheter; when subject no longer requires an external drain, assessed up to 90 days.

Secondary outcomes

  1. Subject transport while on the SED system.

    Evaluating subject transport while on the SED system, specifically, the number of minutes a subject will require clamping of the drain while being transported.

    Time frame: Subject transport review and data collection will begin when the patient is moved from their primary hospital bed location until they reach a new secondary location or are returned to the primary location. Assessed up to 90 days.

  2. Evaluating SED system control throughout duration of study.

    SED system control will be evaluated from initiation of ICP management through discharge of the subject's external drain.

    Time frame: The study review and data collection period will begin at the time SED is connected to the ventriculostomy catheter until discharge of ventriculostomy catheter; when subject no longer requires an external drain, assessed up to 90 days.

07

Study locations

3 sites
  • Texas Children's Hospital
    Houston, Texas 77030, United States
  • Seattle Children's Hospital
    Seattle, Washington 98105, United States
  • University of Washington School of Medicine, Harborview Medical Center
    Seattle, Washington 98195, United States
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2018 to primary completion in Nov 2018, 8 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 28, 2018
First posted
Mar 21, 2018
StartActual
Feb 28, 2018
Primary completionActual
Nov 1, 2018
CompletionActual
Nov 1, 2018
Last update
Jul 11, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 11, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03471702
Lead sponsor
Aqueduct Critical Care
Responsible party
Sponsor
First posted
Mar 21, 2018
Start date
Feb 28, 2018
Primary completion
Nov 1, 2018
Completion
Nov 1, 2018
Last update
Jul 11, 2019

Study contacts

Sam Browd, MD, PhD
study director · Aqueduct Critical Care, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion